Quantitative Investment Management LLC Takes $1.30 Million Position in Halozyme Therapeutics, Inc. $HALO

Quantitative Investment Management LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,631 shares of the biopharmaceutical company’s stock, valued at approximately $1,301,000.

Several other institutional investors and hedge funds have also bought and sold shares of HALO. Horizon Investment Services LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter worth $2,254,000. Mizuho Markets Americas LLC grew its holdings in Halozyme Therapeutics by 270.8% in the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after acquiring an additional 926,526 shares during the last quarter. Chase Investment Counsel Corp bought a new stake in Halozyme Therapeutics in the 2nd quarter worth $2,035,000. Great Lakes Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at about $2,821,000. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Halozyme Therapeutics by 19,326.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock valued at $5,753,000 after acquiring an additional 85,036 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HALO has been the subject of several research analyst reports. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, August 14th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 42,478 shares of company stock valued at $3,767,304. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $106.49 on Tuesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $109.66. The firm’s 50-day simple moving average is $87.76 and its two-hundred day simple moving average is $74.93. The stock has a market cap of $12.09 billion, a PE ratio of 31.79, a price-to-earnings-growth ratio of 0.42 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the business posted $1.54 EPS. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.